| Patient | Richard Roundtree |
|---|---|
| Date of birth | 1975-07-09 |
| Identifiers | MRN HR-ML015-SYN; SSN (made up) 000-15-8410 |
| Document date | 2026-11-01 |
| Author | Leon Carrington, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New painless lump under the left nipple in a man of 51. Concerns: Found a small, painless lump under the left nipple in the shower a few days ago; at first put it down to the breast enlargement he had at 13; Embarrassed to bring up a breast lump and did not think a man could have breast cancer; worried that a diagnosis could cost him work and wants it kept private. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain after surgery, no more than 3 g a day | Two tablets every 6 hours as needed | Oral route | 2026-10-07 to 2026-10-17 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Diagnostic mammography of both breasts: 1.6 cm irregular, spiculated retroareolar mass eccentric to the left nipple (BI-RADS 5); right breast with no mass and no gynecomastia (BI-RADS 1) | 2026-09-30 to 2026-09-30 | completed | S |
| Ultrasound of both breasts and both axillae: 1.5 cm irregular hypoechoic mass with angular margins next to the left nipple; one left axillary lymph node with a thickened cortex; right breast and right axilla normal | 2026-09-30 to 2026-09-30 | completed | S |
| Ultrasound-guided core needle biopsy of the left breast mass and the left axillary node: invasive ductal carcinoma, grade 3; estrogen receptor 95 percent, progesterone receptor 85 percent, HER2 1+ (negative), Ki-67 30 percent; the node contains metastatic carcinoma | 2026-09-30 to 2026-09-30 | completed | S |
| Mastectomy with level I and II axillary lymph node dissection for left breast cancer. Pathology of the left breast: invasive ductal carcinoma 1.6 cm, grade 3, margins clear, no lymphovascular invasion; 2 of 15 lymph nodes involved (largest 7 mm), no extranodal extension; pT1c pN1a, stage IIA | 2026-10-07 to 2026-10-07 | completed | S |
| Transthoracic echocardiogram before anthracycline chemotherapy: left ventricular ejection fraction 62 percent; normal valves and wall motion | 2026-10-23 to 2026-10-23 | completed | S |
| Advance care planning conversation, about 20 minutes | 2026-10-27 to 2026-10-27 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2021-06-15 | Tdap vaccine | completed | S |
| 2026-10-27 | Influenza vaccine, 2026-2027 season (inactivated) | completed | S |
| 2026-10-27 | COVID-19 mRNA vaccine, 2026-2027 formula | completed | S |
| 2026-10-27 | Pneumococcal conjugate vaccine PCV20 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| About 1955 (age 13) | Breast enlargement (gynecomastia) at 13, which he described as due to a hormonal imbalance and as common in boys; no treatment recorded | D (CLM-0003) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| Found a small, painless lump under the left nipple in the shower a few days ago; at first put it down to the breast enlargement he had at 13 | active | S |
| Embarrassed to bring up a breast lump and did not think a man could have breast cancer; worried that a diagnosis could cost him work and wants it kept private | active | S |
Most recent measures: Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-10-27; Hemoglobin [Mass/volume] in Blood 13.9 on 2026-10-20; Leukocytes [#/volume] in Blood by Automated count 7 on 2026-10-20; Neutrophils [#/volume] in Blood by Automated count 4.3 on 2026-10-20; Platelets [#/volume] in Blood by Automated count 281 on 2026-10-20; Sodium [Moles/volume] in Serum or Plasma 139 on 2026-10-05; Potassium [Moles/volume] in Serum or Plasma 4.1 on 2026-10-05; Creatinine [Mass/volume] in Serum or Plasma 0.98 on 2026-10-20; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 93 on 2026-10-20; Glucose [Mass/volume] in Serum or Plasma 92 on 2026-10-05; Calcium [Mass/volume] in Serum or Plasma 9.5 on 2026-10-05; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 21 on 2026-10-20; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 on 2026-10-05; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 71 on 2026-10-05; Bilirubin.total [Mass/volume] in Serum or Plasma 0.6 on 2026-10-20; Albumin [Mass/volume] in Serum or Plasma 4.3 on 2026-10-20; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 on 2026-10-20; Total score [AUDIT-C] 2 on 2026-10-27; Cholesterol [Mass/volume] in Serum or Plasma 186 on 2026-10-27; Cholesterol in HDL [Mass/volume] in Serum or Plasma 56 on 2026-10-27; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 112 on 2026-10-27; Triglyceride [Mass/volume] in Serum or Plasma 90 on 2026-10-27; Hemoglobin A1c/Hemoglobin.total in Blood 5.3 on 2026-10-27 [S]
Strengths and supports: Supports: close friends and family; wants the diagnosis kept private for now [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Invasive ductal carcinoma of the left male breast, central (retroareolar) portion, presenting as a 1.5 cm firm, painless lump eccentric to the left nipple with a palpable left axillary node; core biopsy: grade 3, ER positive, PR positive, HER2 negative, with metastatic carcinoma in the node; clinical stage IIA (cT1c cN1 M0); synthetic modern detail linked to his publicly disclosed breast cancer | active | confirmed | C50.122 | S — Synthetic size, grade, receptor status, and stage; the left-sided lump, the operation, and the spread to lymph nodes are from his public account (D). |
| Estrogen receptor-positive status of the breast cancer | active | confirmed | Z17.0 | S — Synthetic receptor result; his tumor biology was not made public. |
| New firm, painless lump of about 1.5 cm just off the left nipple, with a palpable left axillary node; suspected breast cancer, imaging and core biopsy booked | resolved | confirmed | N63.42 | S — Synthetic presenting concern at the index visit, superseded by the biopsy diagnosis; the left-sided lump is from his public account (D). |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-09-29 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-10-05 | Hemoglobin [Mass/volume] in Blood | 14.8 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-10-05 | Leukocytes [#/volume] in Blood by Automated count | 6.6 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-10-05 | Neutrophils [#/volume] in Blood by Automated count | 3.9 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-10-05 | Platelets [#/volume] in Blood by Automated count | 246 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-10-05 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-10-05 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-05 | Creatinine [Mass/volume] in Serum or Plasma | 1.02 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-10-05 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 89 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-10-05 | Glucose [Mass/volume] in Serum or Plasma | 92 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-10-05 | Calcium [Mass/volume] in Serum or Plasma | 9.5 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-10-05 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-55 U/L | Normal | S |
| 2026-10-05 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 8-48 U/L | Normal | S |
| 2026-10-05 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 71 | U/L | 40-129 U/L | Normal | S |
| 2026-10-05 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-10-05 | Albumin [Mass/volume] in Serum or Plasma | 4.4 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-10-05 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 2026-10-20 | Hemoglobin [Mass/volume] in Blood | 13.9 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-10-20 | Leukocytes [#/volume] in Blood by Automated count | 7 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-10-20 | Neutrophils [#/volume] in Blood by Automated count | 4.3 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-10-20 | Platelets [#/volume] in Blood by Automated count | 281 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-10-20 | Creatinine [Mass/volume] in Serum or Plasma | 0.98 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-10-20 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 93 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-10-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | 7-55 U/L | Normal | S |
| 2026-10-20 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-10-20 | Albumin [Mass/volume] in Serum or Plasma | 4.3 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-10-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-10-27 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-10-27 | Total score [AUDIT-C] | 2 | {score} | S | ||
| 2026-10-27 | Cholesterol [Mass/volume] in Serum or Plasma | 186 | mg/dL | <=200 mg/dL | Normal | S |
| 2026-10-27 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 56 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-10-27 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 112 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-10-27 | Triglyceride [Mass/volume] in Serum or Plasma | 90 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-10-27 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.3 | % | <=5.6% | Normal | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-09-29 | Body height | 188 | cm | S |
| 2026-09-29 | Body weight | 86 | kg | S |
| 2026-09-29 | Body mass index (BMI) [Ratio] | 24.3 | kg/m2 | S |
| 2026-09-29 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-09-29 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-09-29 | Heart rate | 74 | /min | S |
| 2026-09-29 | Respiratory rate | 14 | /min | S |
| 2026-09-29 | Body temperature | 36.7 | Cel | S |
| 2026-09-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-10-05 | Body height | 188 | cm | S |
| 2026-10-05 | Body weight | 85.6 | kg | S |
| 2026-10-05 | Body mass index (BMI) [Ratio] | 24.2 | kg/m2 | S |
| 2026-10-05 | Systolic blood pressure | 134 | mm[Hg] | S |
| 2026-10-05 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-10-05 | Heart rate | 82 | /min | S |
| 2026-10-05 | Respiratory rate | 16 | /min | S |
| 2026-10-05 | Body temperature | 36.8 | Cel | S |
| 2026-10-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-10-20 | Body height | 188 | cm | S |
| 2026-10-20 | Body weight | 84.8 | kg | S |
| 2026-10-20 | Body mass index (BMI) [Ratio] | 24 | kg/m2 | S |
| 2026-10-20 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-10-20 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-10-20 | Heart rate | 76 | /min | S |
| 2026-10-20 | Respiratory rate | 14 | /min | S |
| 2026-10-20 | Body temperature | 36.7 | Cel | S |
| 2026-10-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-10-27 | Body height | 188 | cm | S |
| 2026-10-27 | Body weight | 85 | kg | S |
| 2026-10-27 | Body mass index (BMI) [Ratio] | 24 | kg/m2 | S |
| 2026-10-27 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-10-27 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-10-27 | Heart rate | 72 | /min | S |
| 2026-10-27 | Respiratory rate | 14 | /min | S |
| 2026-10-27 | Body temperature | 36.6 | Cel | S |
| 2026-10-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-09-29 | New painless lump under the left nipple in a man of 51 | finished | S |
| 2026-10-05 | Biopsy results: breast cancer; surgical oncology consultation; germline test and preparation for surgery | finished | S |
| 2026-10-20 | Review two weeks after mastectomy and axillary dissection: pathology, wound and arm care, and preparation for chemotherapy | finished | S |
| 2026-10-27 | Periodic adult preventive visit before chemotherapy | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Urgent surgical oncology (breast) consultation for a suspected breast cancer with an abnormal left axillary node, core biopsy pending, to plan the operation and the axilla | completed | GL-ASCO-MBC-2020, GL-NCCN-BREAST-2025 | S |
| Same-week diagnostic mammography and ultrasound of both breasts and both axillae, and ultrasound-guided core biopsy of the mass and the abnormal node with ER, PR, and HER2 testing | completed | GL-ASCO-MBC-2020, GL-NCCN-BREAST-2025 | S |
| Genetic counseling and germline multigene panel testing (including BRCA2, BRCA1, PALB2, CHEK2, and ATM), as for every man with breast cancer, with a letter for relatives if a variant is found | completed | GL-ASCO-MBC-2020, GL-ASCO-SSO-GERM-2024 | S |
| Mastectomy with axillary lymph node dissection, then shoulder exercises and lymphedema risk reduction with arm measurements at each visit | completed | GL-NCCN-BREAST-2025, GL-ACS-ASCO-SURV-2016 | S |
| Adjuvant chemotherapy given by medical oncology (doxorubicin and cyclophosphamide every three weeks for four cycles, then weekly paclitaxel for twelve weeks, about six months), after a baseline echocardiogram, hepatitis B screening, vaccines, and a dental review; radiation oncology review of post-mastectomy radiation after chemotherapy | completed | GL-NCCN-BREAST-2025, GL-ASCO-CARDIO-2017, GL-ASCO-HBV-2020 | S |
| Tamoxifen after chemotherapy for at least five years, the first-choice endocrine therapy for men, with venous thromboembolism, mood, hot flash, sexual side effect, and adherence checks at every visit | completed | GL-ASCO-MBC-2020, GL-CMID-2026 | S |
| Distress screening at each visit, plain information that men get breast cancer, confidential handling of his diagnosis at work, and the offer of a peer-support group for men with breast cancer | completed | GL-ACS-ASCO-SURV-2016, GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Tissue diagnosis within one week of presentation | 2026-10-05 | completed | Imaging and core biopsy the day after presentation; diagnosis explained on the sixth day | S |
| Curative surgery within two weeks of diagnosis, with lymphedema prevention taught | 2026-10-20 | completed | Mastectomy and axillary dissection two days after the diagnosis; clear margins; arm exercises and risk reduction taught | S |
| Complete germline genetic testing with counseling before chemotherapy starts | 2026-10-27 | active | Panel sent on the day of diagnosis; result not yet back at the end of the episode | S |
| Be ready to start adjuvant chemotherapy within six weeks of surgery: echocardiogram, hepatitis B screening, vaccines, and dental review done | 2026-10-27 | active | Echocardiogram normal; vaccines and hepatitis B screening at the preventive visit; dental review booked; first cycle scheduled | S |